BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 1963272)

  • 1. Pirarubicin phase II study in untreated metastatic small-cell lung carcinoma. A cooperative study of the Groupe Français de Pneumo-Cancérologie (GFPC).
    Kleisbauer JP; Vergeret J; Balmes P; Arnaud A; Taytard A; Targhetta R; Thomas P; Bonnaud F; Poirier R; Touron D
    Am J Clin Oncol; 1990; 13 Suppl 1():S20-3. PubMed ID: 1963272
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I study with combination therapy of pirarubicin, etoposide, and vincristine in small-cell lung cancer.
    Patzer DC; Koschel G; Greifenberg B; Kaukel E
    Am J Clin Oncol; 1990; 13 Suppl 1():S24-8. PubMed ID: 1963273
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of pirarubicin in untreated metastatic small cell lung carcinoma. Groupe Français de Pneumo-Cancérologie (GFPC).
    Kleisbauer JP; Vergeret J; Balmes P; Reynaud-Gaubert M; Taytard A; Targhetta R; Thomas P; Bonnaud F; Poirier R
    Eur J Cancer; 1991; 27(7):943. PubMed ID: 1657080
    [No Abstract]   [Full Text] [Related]  

  • 4. Pilot study of cyclophosphamide-doxorubicin-vincristine-cisplatin-etoposide hybrid chemotherapy in small cell lung cancer.
    Ohnoshi T; Hiraki S; Ueoka H; Kiura K; Kamei H; Horiguchi T; Kodani T; Maeda T; Tabata M; Shibayama T
    Cancer; 1993 Sep; 72(5):1597-601. PubMed ID: 8394202
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [A phase II trial of pirarubicin in untreated disseminated small cell lung cancer. A cooperative study of the French Pneumo-Cancerology Group].
    Kleisbauer JP; Taytard A; Balmes P; Reynaud-Gaubert M; Vergeret J; Targhetta R; Thomas P; Bonnaud F; Poirier R
    Rev Mal Respir; 1992; 9(2):179-84. PubMed ID: 1314404
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I study of paclitaxel, etoposide, and cisplatin in extensive stage small cell lung cancer.
    Kelly K; Pan Z; Wood ME; Murphy J; Bunn PA
    Clin Cancer Res; 1999 Nov; 5(11):3419-24. PubMed ID: 10589753
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized, controlled phase III study of cyclophosphamide, doxorubicin, and vincristine with etoposide (CAV-E) or teniposide (CAV-T), followed by recombinant interferon-alpha maintenance therapy or observation, in small cell lung carcinoma patients with complete responses.
    Tummarello D; Mari D; Graziano F; Isidori P; Cetto G; Pasini F; Santo A; Cellerino R
    Cancer; 1997 Dec; 80(12):2222-9. PubMed ID: 9404698
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of topotecan in patients with extensive-stage small-cell carcinoma of the lung: an Eastern Cooperative Oncology Group Trial.
    Schiller JH; Kim K; Hutson P; DeVore R; Glick J; Stewart J; Johnson D
    J Clin Oncol; 1996 Aug; 14(8):2345-52. PubMed ID: 8708727
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [A pilot study of etoposide, split-dose cisplatin and THP in small cell lung cancer].
    Matsui Y; Satake N; Kusume K; Kado M; Ohshima S; Yamamoto Y; Ishida H; Matsubara Y; Ikeda S
    Gan To Kagaku Ryoho; 1991 Dec; 18(15):2567-72. PubMed ID: 1660701
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer.
    Ihde DC; Mulshine JL; Kramer BS; Steinberg SM; Linnoila RI; Gazdar AF; Edison M; Phelps RM; Lesar M; Phares JC
    J Clin Oncol; 1994 Oct; 12(10):2022-34. PubMed ID: 7931470
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cisplatin/etoposide versus ifosfamide/etoposide combination chemotherapy in small-cell lung cancer: a multicenter German randomized trial.
    Wolf M; Havemann K; Holle R; Gropp C; Drings P; Hans K; Schroeder M; Heim M; Dommes M; Mende S
    J Clin Oncol; 1987 Dec; 5(12):1880-9. PubMed ID: 2824710
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of ifosfamide, carboplatin, and oral etoposide chemotherapy for extensive-disease small-cell lung cancer: an Eastern Cooperative Oncology Group pilot study.
    Wolff AC; Ettinger DS; Neuberg D; Comis RL; Ruckdeschel JC; Bonomi PD; Johnson DH
    J Clin Oncol; 1995 Jul; 13(7):1615-22. PubMed ID: 7602350
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distinctive potentiating effects of cisplatin and/or ifosfamide combined with etoposide in human small cell lung carcinoma xenografts.
    Nemati F; Livartowski A; De Cremoux P; Bourgeois Y; Arvelo F; Pouillart P; Poupon MF
    Clin Cancer Res; 2000 May; 6(5):2075-86. PubMed ID: 10815935
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Schedule dependency of 21-day oral versus 3-day intravenous etoposide in combination with intravenous cisplatin in extensive-stage small-cell lung cancer: a randomized phase III study of the Cancer and Leukemia Group B.
    Miller AA; Herndon JE; Hollis DR; Ellerton J; Langleben A; Richards F; Green MR
    J Clin Oncol; 1995 Aug; 13(8):1871-9. PubMed ID: 7636529
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Experience of a German multicenter study group with ifosfamide in small cell lung cancer.
    Havemann K; Wolf M; Drings P; Hans K; Schroeder M; Holle R; Flechtner H; Goerg R; Becker H
    Semin Oncol; 1989 Feb; 16(1 Suppl 3):9-18. PubMed ID: 2539648
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cisplatin and etoposide (VP-16) as a single regimen for small cell lung cancer. A phase II trial.
    Boni C; Cocconi G; Bisagni G; Ceci G; Peracchia G
    Cancer; 1989 Feb; 63(4):638-42. PubMed ID: 2536584
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of irinotecan plus cisplatin induction followed by concurrent twice-daily thoracic irradiation with etoposide plus cisplatin chemotherapy for limited-disease small-cell lung cancer.
    Han JY; Cho KH; Lee DH; Kim HY; Kim EA; Lee SY; Lee JS
    J Clin Oncol; 2005 May; 23(15):3488-94. PubMed ID: 15908658
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concurrent cisplatin, prolonged oral etoposide, and vincristine plus chest and brain irradiation for limited small cell lung cancer: a phase II study of the Southwest Oncology Group (SWOG-9229).
    Thomas CR; Giroux DJ; Stelzer KJ; Craig JB; Laufman LR; Taylor SA; Goodwin JW; Crowley JJ; Livingston RB
    Int J Radiat Oncol Biol Phys; 1998 Mar; 40(5):1039-47. PubMed ID: 9539558
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cisplatin and etoposide alternating ifosfamide, vincristine, epirubicin in small cell lung cancer.
    Unsal M; Erturk D
    Saudi Med J; 2003 Jun; 24(6):628-31. PubMed ID: 12847592
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trial of paclitaxel and carboplatin in metastatic small-cell lung cancer: a Groupe Français de Pneumo-Cancérologie study.
    Thomas P; Castelnau O; Paillotin D; Léna H; Robinet G; Muir JF; Delaval P; Gouva S; Balmes P; Blanchon F; Perdu D; Poirier R; Pommier De Santi P; Penot-Ragon C; Kleisbauer JP
    J Clin Oncol; 2001 Mar; 19(5):1320-5. PubMed ID: 11230474
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.